Fourteen people have died and 273 have been injured as a result of biological material building up over time in the grafts connecting both HeartMate II and HeartMate 3 left ventricular assist device ...

Add Yahoo as a preferred source to see more of our stories on Google. About 14,000 of the HeartMate II and HeartMate 3, manufactured by Thoratec Corp., a subsidiary of Abbott Laboratories, are thought ...

(NEXSTAR) – The Food and Drug Administration (FDA) announced Monday that two heart pump products are being recalled after reports of 14 deaths and hundreds of injuries were associated with the devices ...

CLEVELAND, OH — Researchers are warning about "unexpectedly" and "abruptly" increased rates of thrombosis with the HeartMate II (Thoratec) left ventricular assist device (LVAD) occurring early after ...

Good news for the HeartMate 3 (Abbott Cardiovascular) as a bridge to heart transplantation: in the 2 years following US Food and Drug Administration approval of the left ventricular assist device ...

A pair of heart devices linked to hundreds of injuries and at least 14 deaths has received the FDA’s most serious recall, the agency announced Monday. The recall comes years after surgeons say they ...

The long-term use of ventricular assist devices is becoming a problem for at least some of these devices, as demonstrated by the recall of the Heartmate II and Heartmate 3 devices by Abbott ...

Trialists and journalists, practitioners and bloggers really appreciate a soundly positive trial. MOMENTUM-3, presented at the American College of Cardiology 2018 Annual Scientific Sessions, fit that ...

Thoratec (Pleasanton, CA) released positive Q3 results. In part, results were boosted by the company's HeartMate pump product line.For the quarter, Thoratec landed revenues of $126.4 million. This ...

ABBOTT PARK, Ill., Aug. 29, 2022 /PRNewswire/ -- Abbott today announced new late-breaking data that show its HeartMate 3™ heart pump extends survival of advanced heart failure patients by at least ...

ORLANDO, Florida (Reuters) - Advanced heart failure patients who received Thoratec Corp's new pump awaiting U.S. approval as an alternative to heart transplants lived longer and fared far better than ...